USMCA Watch: Pharma Pricing Issues Add To The Pile Of Passage Problems — Panjiva


USMCA Watch: Pharma Pricing Issues Add To The Pile Of Passage Problems

Canada 338 Health Care 108 Mexico 505 Trade Deals 702 U.S. 3297 USMCA 373

The U.S. Trade Representative has taken the unusual move of stating that revised U.S.-Mexico-Canada Agreement (USMCA) rules on biologic drug patent protections do not change regulations for drug pricing in the U.S. That’s likely a response to House Democrats’ concerns and comes against the backdrop of other issues such as labor protection that may hold up USMCA’s passage through Congress. Aside from intellectual property rights the trade of pharmaceuticals in USMCA is minor in context. Imports from Canada and Mexico accounted for just 6.3% of the total $71.2 billion imp...

PANJIVA RESEARCH is a service provided by Panjiva, Inc. ("Panjiva") to relevant global subscribers, and are deemed to be Panjiva "Services" subject to the Panjiva Terms & Conditions of Use. Information contained within or made available via the Services is for informational purposes only and nothing in the Services shall constitute or be construed as an offering of financial instruments, or as investment advice or recommendations by Panjiva, Inc. or its affiliates of an investment strategy or whether to "buy", "sell" or "hold" an investment. The Services may include views and commentary about customers of Panjiva. No aspect of the Services is based on consideration of your individual circumstances, and you should determine on your own whether you agree with the information contained within or made available via the Services. Employees involved in Panjiva Research may hold positions in securities analyzed or discussed in the Services. Panjiva does not make any express or implied warranties, representations, endorsements or conditions with respect to the Services and the information contained within or made available via the Services, including without limitation, warranties as to the usefulness, completeness, accuracy, currentness, reliability or sufficiency of any information (including, without limitation, conclusions, statements, opinions, estimates, forecasts or projections of any kind) and expressly disclaims any implied warranties. Neither this disclaimer nor any of its contents may be forwarded or redistributed without the prior written consent of Panjiva. © 2019 Panjiva, Inc. All Rights Reserved.